Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case report
Dupilumab, a monoclonal antibody that targets interleukin-4 and interleukin-13, is one of the approved biologic treatments for moderate-to-severe atopic dermatitis. While it is extremely well tolerated with low rates of adverse events, there have been reports of patients with atopic dermatitis manag...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-02-01
|
| Series: | SAGE Open Medical Case Reports |
| Online Access: | https://doi.org/10.1177/2050313X251317811 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832542884010655744 |
|---|---|
| author | Katrina D Cirone Fiona E Lovegrove |
| author_facet | Katrina D Cirone Fiona E Lovegrove |
| author_sort | Katrina D Cirone |
| collection | DOAJ |
| description | Dupilumab, a monoclonal antibody that targets interleukin-4 and interleukin-13, is one of the approved biologic treatments for moderate-to-severe atopic dermatitis. While it is extremely well tolerated with low rates of adverse events, there have been reports of patients with atopic dermatitis managed on Dupilumab developing new-onset psoriasis. The development of psoriasis in patients with atopic dermatitis on Dupilumab therapy is believed to occur due to a decrease in T helper 2 activity and resultant dysregulation of the T helper 1 and T helper 17 pathways involved in psoriasis pathogenesis. Upadacitinib, an oral, selective Janus kinase 1 inhibitor, approved for use in moderate-to-severe atopic dermatitis as well as psoriatic arthritis may have a potential role in psoriasis treatment. We describe a case of a patient who initially presented with longstanding atopic dermatitis that underwent a psoriasiform switch while managed on Dupilumab and is currently stable on Upadacitinib. |
| format | Article |
| id | doaj-art-2e86166d195448248ab7d6c2c9158dee |
| institution | Kabale University |
| issn | 2050-313X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | SAGE Open Medical Case Reports |
| spelling | doaj-art-2e86166d195448248ab7d6c2c9158dee2025-02-03T14:03:33ZengSAGE PublishingSAGE Open Medical Case Reports2050-313X2025-02-011310.1177/2050313X251317811Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case reportKatrina D Cirone0Fiona E Lovegrove1Schulich School of Medicine & Dentistry, Western University, London, ON, CanadaLovegrove Dermatology, London, ON, CanadaDupilumab, a monoclonal antibody that targets interleukin-4 and interleukin-13, is one of the approved biologic treatments for moderate-to-severe atopic dermatitis. While it is extremely well tolerated with low rates of adverse events, there have been reports of patients with atopic dermatitis managed on Dupilumab developing new-onset psoriasis. The development of psoriasis in patients with atopic dermatitis on Dupilumab therapy is believed to occur due to a decrease in T helper 2 activity and resultant dysregulation of the T helper 1 and T helper 17 pathways involved in psoriasis pathogenesis. Upadacitinib, an oral, selective Janus kinase 1 inhibitor, approved for use in moderate-to-severe atopic dermatitis as well as psoriatic arthritis may have a potential role in psoriasis treatment. We describe a case of a patient who initially presented with longstanding atopic dermatitis that underwent a psoriasiform switch while managed on Dupilumab and is currently stable on Upadacitinib.https://doi.org/10.1177/2050313X251317811 |
| spellingShingle | Katrina D Cirone Fiona E Lovegrove Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case report SAGE Open Medical Case Reports |
| title | Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case report |
| title_full | Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case report |
| title_fullStr | Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case report |
| title_full_unstemmed | Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case report |
| title_short | Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case report |
| title_sort | dupilumab induced psoriasis in a patient with atopic dermatitis successfully treated with upadacitinib a case report |
| url | https://doi.org/10.1177/2050313X251317811 |
| work_keys_str_mv | AT katrinadcirone dupilumabinducedpsoriasisinapatientwithatopicdermatitissuccessfullytreatedwithupadacitinibacasereport AT fionaelovegrove dupilumabinducedpsoriasisinapatientwithatopicdermatitissuccessfullytreatedwithupadacitinibacasereport |